By admin 
The landscape of American pharmaceutical regulation underwent a significant shift this week as a Food and Drug Administration (FDA) advisory panel recommended that compounding pharmacies be permitted to manufacture several popular but unapproved peptides, signaling a victory for advocates of expanded access to alternative treatments. On Friday, the Pharmacy Compounding Advisory Committee (PCAC) voted to recommend the inclusion of the peptides epitalon and semax on the list of substances that pharmacies can use in bulk for compounding, though it stopped short of endorsing emideltide. These recommendations come at a pivotal moment for the Department of Health and Human Services (HHS), as Secretary Robert F. Kennedy Jr. continues his mission to overhaul the nation’s health priorities under the "Make America Healthy Again" (MAHA) banner.
The two-day meeting in Washington served as a microcosm of the broader ideological struggle currently playing out within the federal government. On one side are career FDA scientists and academic researchers who emphasize the necessity of rigorous, double-blind clinical trials to establish safety and efficacy. On the other side are wellness-focused practitioners, industry representatives, and political appointees who argue that patient autonomy and real-world clinical experience should carry more weight, particularly for substances that have already gained a foothold in the "grey market" of internet-driven wellness.
Peptides, which are short chains of amino acids that act as signaling molecules in the body, have seen an explosion in popularity over the last several years. Often marketed for their purported anti-aging, performance-enhancing, and cognitive-boosting properties, these compounds have transitioned from the fringes of bodybuilding forums to mainstream wellness clinics. According to a recent survey by Sermo, nearly half of U.S. physicians report that their patients are currently using non-FDA-regulated peptides, a trend largely fueled by social media influencers and the "biohacking" community. Despite this high usage, the FDA has historically maintained a restrictive stance, citing a lack of standardized dosing, manufacturing quality control, and long-term safety data.
Friday’s deliberations focused on three specific substances. Epitalon, a synthetic version of the pineal peptide epithalamin, was considered for the treatment of insomnia. Supporters of the peptide point to its purported ability to regulate melatonin production and lengthen telomeres, though career FDA staff noted that the evidence for these claims remains largely anecdotal or based on small-scale studies conducted decades ago. Nevertheless, the panel voted 7-4 to recommend its addition to the 503A bulk drug substances list, which allows compounding pharmacies to create customized medications for individual patients using the raw ingredient.
The panel also considered semax, a synthetic heptapeptide originally developed in Russia. Semax has gained a significant following for its alleged neuroprotective and nootropic effects, with proponents seeking its use for migraines, cerebral ischemia, and trigeminal neuralgia. During the public comment period, semax received vociferous support from patients who claimed it had succeeded where traditional medications had failed. Some commenters pointed out that semax is already approved for clinical use in Russia, suggesting that a wealth of data already exists. However, FDA reviewers countered that much of the available research does not meet the stringent "substantial evidence" standard required for U.S. approval, noting inconsistencies in study design and reporting. Despite these concerns, the panel voted 8-5 in favor of allowing it to be compounded.
The only peptide to face a rejection on Friday was emideltide, which was being considered for the treatment of opioid withdrawal, chronic insomnia, and narcolepsy. The vote was a narrow 6-7 against its inclusion. The dissenting voices, which included David Pope, the chief pharmacy officer at XiFin Pharmacy Solution, expressed concern over the "potentially dangerous downstream consequences" of allowing a substance with such powerful neurological implications to be compounded without more robust safety guardrails. Pope, who had voted in favor of other peptides during the session, noted that the risks associated with emideltide’s use in vulnerable populations, such as those suffering from opioid addiction, outweighed the potential benefits of expanded access.
These Friday votes followed a similarly active session on Thursday, where the panel recommended several other high-profile peptides. BPC-157, a peptide derived from human gastric juice that is widely used in the fitness community for injury recovery, was recommended for the treatment of ulcerative colitis by an 8-6 vote. The panel also gave the green light to KPV, a peptide known for its anti-inflammatory properties in wound healing, and TB-500, a synthetic version of thymosin beta-4 often used for tissue repair. Additionally, MOTS-c, a mitochondrial-derived peptide, was recommended for use in treating obesity and osteoporosis by a 7-5 margin.
The composition of the panel itself was a point of contention throughout the proceedings. Many of the "yes" voters were appointed by the Health and Human Services Department under the current administration and possessed professional ties to the peptide and wellness industries. These members frequently argued that the committee’s mandate was not to "approve" a drug in the traditional sense, but rather to determine if there is a clinical need that justifies allowing pharmacies to compound it. Asare Christian, a physical medicine and rehabilitation physician and founder of the wellness clinic Aether Medicine, encapsulated this view during the debate. "We’re talking about dosing and efficacy and safety, and it doesn’t look like that’s what we’ve been asked to do," Christian said. "As a physician, my view is through the lens of the patient in front of me."
This patient-centric approach stands in stark contrast to the perspective of career FDA staff. Mary Thanh Hai, the director of the Office of New Drugs, repeatedly warned that adding these substances to the 503A list effectively bypasses the agency’s ability to monitor safety. Under current law, once a substance is placed on the bulk list for compounding, the FDA has no authority to require the manufacturers or pharmacies to submit ongoing safety or efficacy data. "In the grey market, that’s not a requirement to be sent to us," Thanh Hai noted. "Even getting on to the 503A compounding list, that isn’t a requirement."
The potential for political influence to override scientific consensus is a looming shadow over the FDA’s next steps. While the agency is not legally bound to follow the recommendations of its advisory panels, the current political climate suggests that the traditional deference to career staff may be waning. Robert F. Kennedy Jr. has been a vocal critic of what he calls "regulatory capture" within the FDA, arguing that the agency has become a barrier to innovative and natural treatments. With acting FDA commissioner Kyle Diamantas at the helm—a figure seen as more aligned with the administration’s deregulatory agenda—there is a high probability that the panel’s recommendations will be adopted.
If the FDA moves forward with these recommendations, it will publish a proposed rule in the Federal Register, opening a period for public comment. This process is expected to be contentious, as academic medical centers and patient safety advocates are likely to voice strong opposition. Dissenting panelists, many of whom are physicians from prestigious academic institutions, expressed fear that allowing the compounding of these peptides would turn the American public into a giant, unregulated clinical trial. They argued that without standardized dosing and clear indications, physicians would be "flying blind," potentially leading to adverse reactions that go unreported.
The debate over peptides also touches on the economics of the pharmaceutical industry. Compounded medications are often cheaper than patented, FDA-approved drugs, but they also lack the same level of insurance coverage. By moving these peptides onto the 503A list, the administration may be attempting to formalize a market that already exists in the shadows, potentially bringing more oversight to the manufacturing process even if the clinical data remains sparse. However, critics argue that this "middle ground" is a dangerous compromise that erodes the gold standard of evidence-based medicine.
As the "Make America Healthy Again" movement gains momentum, the FDA finds itself at a crossroads. The decisions made regarding these peptides could set a precedent for how other unapproved substances—from supplements to experimental biologics—are regulated in the future. For now, the peptide industry and its supporters are celebrating what they see as a long-overdue acknowledgment of patient choice and clinical innovation. Meanwhile, the scientific community remains on high alert, watching to see how the tension between political will and traditional regulation will reshape the future of American healthcare.
